title: Alterations of Serum IP-10 and TARC in Patients with Early Acute Rejection after Liver Transplantation.
abstract: OBJECTIVE
  To analyze alterations of interferon-γ-induced protein 10 (IP-10) and thymus and activation-regulated chemokine (TARC) levels in early acute liver transplantation rejection.
  
  
  METHODS
  Thirty-six patients with early acute liver transplantation rejection were classified as non-, mild, moderate, and severe rejection groups. The levels of serum IP-10 and TARC were determined on days 3, 2, 1, and 0 before biopsy.
  
  
  RESULTS
  The IP-10 activities in all rejection groups were significantly higher (p < 0.05) than those in the non-rejection group at all time points and correlated with the extent of rejection (p < 0.05). The differences in TARC among the three rejection groups were significant (p < 0.05), and its highest level was found in the mild rejection group at all observed time points, whereas its lowest level was detected in the severe rejection group. The analysis of the TARC/IP-10 ratio revealed that the volume was correlated with the rejection degree. This ratio in the moderate and severe rejection groups on days 2, 1, and 0 before biopsy were 20% lower than that before transplantation.
  
  
  CONCLUSIONS
  Serum IP-10 showed an increasing trend during early acute liver transplantation rejection. IP-10 increase or TARC/IP-10 ratio decrease combining with abnormal hepatic enzymatic alteration could be a valuable and specific sign for early rejection of the transplanted liver.
authors.forename: Xingchu
authors.initials: X
authors.lastname: Meng
authors.forename: Wei
authors.initials: W
authors.lastname: Gao
authors.forename: Ying
authors.initials: Y
authors.lastname: Tang
authors.forename: Zhongyang
authors.initials: Z
authors.lastname: Shen
authors.forename: Zhenglu
authors.initials: Z
authors.lastname: Wang
mesh_terms: D000293:Adolescent; D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D001663:Bilirubin / Q000097:blood; D015415:Biomarkers / Q000097:blood; D054414:Chemokine CCL17 / Q000097:blood* / Q000235:genetics; D054357:Chemokine CXCL10 / Q000097:blood* / Q000235:genetics; D002908:Chronic Disease; D042241:Early Diagnosis; D005260:Female; D015870:Gene Expression; D006084:Graft Rejection / Q000097:blood* / Q000175:diagnosis* / Q000276:immunology / Q000473:pathology; D048550:Hepatic Insufficiency / Q000473:pathology / Q000601:surgery; D006801:Humans; D008111:Liver Function Tests; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D012720:Severity of Illness Index; D055815:Young Adult
chemical_list: D015415:Biomarkers; C106230:CCL17 protein, human; C114753:CXCL10 protein, human; D054414:Chemokine CCL17; D054357:Chemokine CXCL10; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D001663:Bilirubin
keywords: Interferon-γ-Induced Protein 10; Liver transplant rejection; Thymus and activation-regulated chemokine